Common questions, answered plainly.

Instructional Biology Inc. (iBIO) is a research-stage biotechnology company developing a connected technology stack — a biology-native AI reasoning system paired with a physical bio-processing protocol — aimed at reasoning across biological signaling as a connected system rather than an isolated list of targets.

ASAP is our Advanced Science AI Platform. It organizes biological evidence into a structured, hierarchy-aware graph — the Signaling Cascade Knowledge Graph (SCKG) — so relationships between signals, receptors, cascades, and outcomes can be reasoned about explicitly instead of inferred from a flat list.

MHFBP is a controlled, lower-temperature approach to preserving the native structure of complex biological material during processing, in contrast to legacy methods that trade structural fidelity for industrial throughput. It's the physical-processing layer our reasoning systems depend on having intact evidence to work with.

Five connected layers: the Markosian High-Fidelity Bio-Processing Protocol, a pathogen-reduction system, a carrier (exosome) manufacturing system, the reasoning system (SCKG, reasoned over by ASAP), and a therapeutic-regulation system that operates within a clinician-authorized envelope. See Our Technologies for the full stack.

Instructional Biology Inc. is a research-stage organization. Our platform and programs are under active development and have not completed clinical development. Nothing on this site is a claim of clinical efficacy, regulatory approval, or medical advice — we say that plainly and repeat it often.

Not yet. We're a research-stage company, and our public materials intentionally under-claim rather than overstate where the science stands. If you're a clinician or researcher with a specific question, we welcome it — reach out through our contact page.

The company was founded by Boris Markosian, building on more than a decade of prior work across neuroscience, computational data architecture, and biological operations. Instructional Biology Inc. was formally founded on February 5, 2026, and is based in Oceanside, California. Read more on the founder's story page.

We're building toward pharmaceutical, research, and clinical partnerships. Visit Partnerships & Licensing to see how that process works, or reach out directly and tell us what you're trying to accomplish.

Investor materials are handled directly rather than published on the public site. Email us and we'll follow up personally — we're a small, research-stage team, so expect a real reply rather than an autoresponder.

Email boris@instructionalbiology.com or call (818) 208-0270. You can also use the form on our Contact page — we read every message that comes in.

No. Instructional Biology is a research-stage company: no product has been approved by any regulatory agency, and its platform and programs have not completed clinical development. Nothing on the site is a claim of clinical efficacy or medical advice. Learn more about the company and its stage.

Instructional Medicine is our research thesis for a more context-aware approach to biology: identify how biological signals relate to one another, preserve what they mean, and build around what the system is communicating, rather than forcing a single receptor. It brings our five technology systems together as one integrated program, from AI discovery through manufacturing, delivery and patient-specific feedback. Read the science behind it.

A digital twin in medicine is a computational model of one person's biological signaling, built from their own data, that updates as new signals arrive. It is not a duplicate of a person or a crystal ball; it is a model bounded by the evidence that built it. For Instructional Biology it is a multi-year research direction, and we do not currently offer a digital twin product. Read our digital twins explainer.

No. In our therapeutic-regulation system, closed-loop means the loop closes only within boundaries a clinician has set in advance, a prescriber-authorized envelope. Any signal outside that envelope escalates to a human reviewer rather than triggering an autonomous change. See how the therapeutic-regulation system works.

The Thermosensitive Peptidome, or TSP, is our term for the collection of temperature-sensitive signaling peptides and proteins we seek to protect during processing. These molecules carry their function in their three-dimensional fold, which heat can undo even without breaking a chemical bond. Read the Thermosensitive Peptidome explainer.

Biological signaling forms a hierarchy: a few master regulators, then exponentially more cascades, receptors, peptides, disease states and outcomes. In hyperbolic space, room grows exponentially as you move outward, matching how that hierarchy branches, so the graph fits without crowding. The full graph is embedded in a 16-dimensional Poincaré ball, building on Nickel and Kiela's 2017 work on Poincaré embeddings. Open the interactive Poincaré Explorer.

Yes. Our five technology families do not stand or fall together: two of them, ISRS-ML pathogen reduction and the MET-APFS carrier, operate on third-party material and do not depend on the bioprocessing claims, so a company with its own biologic could license either on its own. All five are available for discussion individually or as a whole. See the five technology families.

For qualified reviewers, including investors, prospective partners and licensees, we maintain a controlled virtual data room with additional non-public material. Access is granted after an introductory conversation, on a qualified, case-by-case basis. Start by emailing us and telling us what you are interested in. Read how the investor reference room works.

Yes. U.S. Utility Patent Application No. 19/793,487 was filed on September 1, 2026, by founder and sole inventor Boris Markosian, and it builds on five previously filed provisional applications. It is a pending application: nothing is a granted patent, and no claim has been examined or allowed. Read the patent filing announcement.

Exosomes are nanoscale, membrane-wrapped particles released by cells, roughly 40 to 160 nanometres across, that carry proteins, lipids, nucleic acids and metabolites. Researchers study them as natural drug-delivery carriers, and our carrier (exosome) manufacturing system builds engineered delivery vesicles modeled on this transport mechanism. Read our exosome explainer.